30 Total Patients Enrolled at 2 Clinical Research Sites in Device Study ALERTS
Our clinical research coordinators and physicians should be proud! One of our sites was 10th nationwide, 5th in enrollment rate.
In collaboration with Katy Cardiology Associates, Dr. Amir Kashani and his partners, we were able to enroll a full 26 patients over the course of the study, which was good enough to be 10th out of 101 total sites nationwide. We were actually 5th out of 101 for our enrollment rate! Since we were not one of the first sites selected, we started out behind but quickly caught up. Considering the potential importance of this device, as well as the caliber of other institutions participating, this is an awesome achievement for our growing research department.
“As we have worked with more and more sponsors of all sizes, we have found that good communication between our team, the physicians, and the sponsor have proven time and time again to be the recipe for success. Because of the close relationship we have with the Principal Investigators at our sites, we often know well in advance if we will be able to recruit patients. We only choose studies that make sense for the patient first and foremost, so recruitment for our sites is rarely a problem. We try to work out all of the details well in advance of site activation, so that once we are able to enroll, we hit the ground running. ”
Angel Medical Systems is an innovator in today's cardiac medical device arena. The company has developed the AngelMed Guardian system, which is designed to detect and warn patients when a heart attack may be imminent.
The study is no longer enrolling patients, but many patients are continuing to be followed through the course of the trial. We are excited to see the outcome of the data as this device has the potential to drastically reduce the time it takes for high-risk patients to recognize they are having a heart attack and seek medical attention immediately. The long-term benefits to patients, if this device works as intended, would be monumental because their risk for developing heart failure following long-term muscle tissue damage would decrease drastically.
*The contents of this post were approved by WIRB 4-16-14.